Insights

How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.

An animated, immersive biosimilar market snapshot with actionable insight for manufacturers.

We asked 100 physicians to share their perspectives on biosimilar utilization, cost savings, and adoption barriers. See what they said and what it means for the market and manufacturers.

Innovative therapies make innovative patient services essential. Learn how Lash Group helped one manufacturer improve speed and access to therapy with an electronic provider portal for benefit verification and prior authorization.

What are the elements of innovative, effective medication adherence programs -- and how do they address the underlying causes of non-adherence?

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

Why do patients struggle with medication adherence even when they know it will help them? In part one of a two-part article series from Lash Group, discover how the most advanced patient support programs use behavioral science to unlock adherence.

Two experts in health economics and patient support team up to offer insight on how manufacturers can prepare for the impact of copay accumulators.

How adherence solutions are evolving -- with some high-tech help. Originally published on FiercePharma.com.

Phase II of DSCSA requires interoperable systems for the electronic tracking of product through the supply chain. Is pharma prepared? Learn what stakeholders need to know and do know to prepare for 2023.

Executive Q&A: The market trends and technology solutions impacting medication adherence today.

Download this new white paper from IHOC - Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies - to learn the key insights about the role HSSPs play in improving the patient experience and why patient and provider satisfaction are important data points for both payers and manufacturers to consider when deciding to include HSSPs in their networks.

Executive Q&A: How shifting coverage for some drugs from Medicare Part B to Part D could impact access and affordability for patients.

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

A collection of AmerisourceBergen's top insights from 2018, including commercialization considerations for novel therapies, emerging trends in retail and specialty pharmacy and best practices for managing inventory in the specialty practice.

Why is accreditation important for patient support program providers?

What are the pitfalls of historic approaches to adherence? Learn how leading solutions combine both measurement and engagement for real results.

Open enrollment for Health Insurance Marketplace plans is here. Do PAP patients know their coverage options?

How leading patient support providers combine measurement with engagement to improve adherence.

The evolving needs of the patient and historic approaches to non-adherence.

How can FTZs help with commercialization success? What should manufacturers consider when evaluating a FTZ and 3PL partner?

What are FTZs and why should pharma use them?

Executive Q&A: how pharmaceutical distributors are compensated and the value they deliver to the healthcare supply chain.

What role does the changing healthcare coverage landscape play in support program demand and design?

Our strategic global sourcing experts explain how proposed new contracting models impact efficiency, and why they may not be ideal for the industry at large.

Much of the complexity of the cell and gene supply chain comes from how dependent the commercialization phase is on the clinical phase. What does integration look like, and how can the right logistics partner help?

Patients face a growing number of barriers that can impede medication access and adherence. How can manufacturers help address these hurdles?

How third-party logistics (3PL) solutions can help cell and gene therapy manufacturers manage the financial aspects of launching new therapies.

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Explore the fundamentals of blockchain and how it could be used by the healthcare industry to achieve DSCSA compliance.

Learn how the right specialty pharmacy can offer value-added services for physician practices and patients.

How manufacturers can benefit from provider-led care coordination to improve patient outcomes.

How do channel strategy decisions impact providers and patients—and how can you ensure a patient-centric commercialization strategy? Our strategic global sourcing experts share insights on how customers respond to channel strategy decisions.

Our experts look at what President Trump's new plan for reducing drug prices means for manufacturers, pharmacies and the drug wholesale industry.

How is manufacturer thinking around channel strategy changing for oral oncolytics?

What manufacturers need to know about how distribution impacts access.

How drug manufacturers, health systems and payers can collaborate more closely in the new world of patient-centered care.

The growing trend toward value-based payment models and ongoing demand for clinical outcomes creates a need for better coordination of care. What challenges does this create for health system specialty pharmacies and what opportunities does this present for demonstrating value?

Insights from managed care executives on the future of coverage and outcomes evaluation.

Xcenda examines payer tactics for managing commercial copay assistance in a new issue brief.

How medication adherence strategies are evolving to meet each individual’s unique needs.

How do manufacturers' distribution decisions ultimately impact patients? What long- and short-term disruption do direct models present? AmerisourceBergen experts offer perspective on the unintended consequences of channel strategy decisions.

Key healthcare and health policy trends to watch in 2018 -- and what they mean for pharmaceutical manufacturers.

Our strategic global sourcing experts share how AmerisourceBergen's leadership in specialty distribution influences the way we partner with manufacturers.

Our experts share what customers wish manufacturers knew about product access.

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

What manufacturers need to know about the customer experience.

What information do payers and providers want from pharma?

Key themes from ThinkLive 2017, AmerisourceBergen's annual manufacturer summit.

How an effective pharmaceutical distribution partnership works.

How pharmaceutical wholesalers have evolved in recent years.

Misconceptions about specialty pharmacy and the importance of meeting patients where they are in their healthcare journey.

How can data-driven service design improve patient support programs and outcomes?

What should biosimilar manufacturers focus on for commercialization success?

What does the future of benefit verification look like for manufacturer patient support programs?

How are payers thinking about apps, wearables and other digital health technologies?

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.

Three factors that could influence biosimilars' commercial success.

Four things to keep in mind for patient support partnerships.

Rich Tremonte on the current healthcare landscape, the role of the wholesaler and how the new organizational structure at AmerisourceBergen brings out the best in both.

Alternative methodologies for coding biosimilars reveal an addition $15.1 billion in hidden savings.

What should manufacturers look for in a specialty pharmacy partner? Learn six ways the right SP can add value.

In supply chain decisions, a wholly new type of product demands a wholly new definition for supply chain expertise and effective support.

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.

Sam Herbert, President of World Courier, shares the factors that are driving trial sponsors to deploy innovative approaches to manage expenses and improve trial success.

Learn the unintended consequences of channel strategy decisions and the impact on patients and providers.

How should manufacturers be using distribution data to uncover insights and manage access?

Explore what it means to put patients at the center of support program design through this interactive experience drawing perspective from real patients and how they view healthcare.

An interview with Matt George, patient advocate and survivor of paroxysmal nocturnal haemoglobinuria (PNH), a debilitating, rare and life-threatening disorder.

Pete Belden, President of ICS, shares how the manufacturer client base for 3PL is changing as a result of the rapid expansion of emerging manufacturers and industry consolidation.

Demonstrate the value of rare disease therapies with these five key ways to connect where patients, physicians and payers perceive the most value.

The five components manufacturers shouldn't ignore when building orphan drug support programs.

New challenges to oncology product access, optimized clinical outcomes and commercial success, with strategic recommendations for how pharmaceutical manufacturers can support prescribers and patients through the continuum of cancer care.

Designing support programs that are truly patient-centric and overcoming obstacles along the way.

Mapping the patient journey and building support programs that address the three biggest hurdles patients face.

How can manufacturers turn patient-centricity from buzzword into reality?

As global manufacturers of specialty pharmaceuticals look to enter the Canadian market, it is important to understand the Canadian healthcare landscape with the provision of patient support services being an important consideration.

Successful commercialization demands that manufacturers address three critical areas of opportunity — evidence, access and adherence.

The globalization of healthcare raises a number of questions for the pharmaceutical industry, from how R&D is changing to how to approach new markets.

How the Group Purchasing Organization (GPO) model has evolved — and what it means for manufacturers.